Core Laboratories Given New $189.00 Price Target at Howard Weil (CLB)
Equities researchers at Howard Weil decreased their price target on shares of Core Laboratories (NYSE:CLB) from $222.00 to $189.00 in a research report issued on Tuesday, AnalystRatingsNetwork.com reports. The firm currently has a “sector outperform” rating on the stock. Howard Weil’s price objective would suggest a potential upside of 13.16% from the company’s current price.
Core Laboratories (NYSE:CLB) opened at 167.02 on Tuesday. Core Laboratories has a 52-week low of $133.02 and a 52-week high of $221.00. The stock has a 50-day moving average of $197.4 and a 200-day moving average of $190.5. The company has a market cap of $7.495 billion and a price-to-earnings ratio of 30.87.
Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $1.35 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.45 by $0.10. The company had revenue of $262.90 million for the quarter, compared to the consensus estimate of $283.02 million. During the same quarter last year, the company posted $1.22 earnings per share. Core Laboratories’s revenue was up .8% compared to the same quarter last year. Analysts expect that Core Laboratories will post $6.17 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, May 23rd. Investors of record on Friday, April 25th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, April 23rd.
CLB has been the subject of a number of other recent research reports. Analysts at RBC Capital cut their price target on shares of Core Laboratories from $235.00 to $180.00 in a research note on Tuesday. They now have a “sector perform” rating on the stock. Separately, analysts at Barclays cut their price target on shares of Core Laboratories from $198.00 to $181.00 in a research note on Monday. Finally, analysts at Morgan Stanley upgraded shares of Core Laboratories from an “underweight” rating to an “equal weight” rating in a research note on Monday. Eleven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $178.33.
Core Laboratories N.V. (NYSE:CLB) is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.